GlobeNewswire by notified

Change of ownership in Micro Systemation AB

Share

Stockholm April 29th, 2021

MSAB has today been informed about an agreement concerning change of ownership in MSAB has been concluded today. AB Grenspecialisten, Edastra AB and Cervantes Capital AB have acquired the total number of Henrik Tjernberg´s A-shares. After the completion of the transaction the major owners in MSAB will be as following:

  • Cervantes Capital AB: (1 544 685 number of B-shares, 127 500 number of A-shares, equivalent to 8,72% of the capital of the company and equivalent to 10,01% of the voting rights)
  • Edastra AB: (1 143 592 number of B-shares, 347 500 number of A-shares, equivalent to 7,78% of the capital of the company and equivalent to 16,39% of the voting rights)
  • Strawberry Capital: (1 450 419 number of B-shares, equivalent to 7,57% of the capital of the company and equivalent to 5,15% of the voting rights)
  • AB Grenspecialisten: (574 612 number of B-shares, 525 000 number of A-shares, equivalent to 5,74% of the capital of the company and equivalent to 20,68% of the voting rights)

“We look forward to continuously support the company and its management team alongside the other shareholders in order to create long-term value”, says David Zaudy and Simon Kjellström, partners at Cervantes.

“We would like to thank Henrik Tjernberg who made MSAB a pioneer in the field of mobile forensics, an area of fundamental importance to the modern society. Being a shareholder in MSAB since 2009, Edastra is enthusiastic to have Grenspecialisten and Cervantes joining us on this long-term journey”, says Robert Ahldin, founder and COB of Edastra AB.

“For a long time, we have been following MSAB and consider it to be a very interesting company”, Martin Gren says and adds; “Our intention is to be a long-term and committed owner”.

“MSAB today provides the best offer within its field of business. It is based on genuine technical competence, the belief in the community of law along with the importance of human rights, but also the need of an effective- and legally secure judicial process. I look forward to, in a new role, continuing to support the company in its future development”, comments Henrik Tjernberg, outgoing COB.

After the completion of the transaction Henrik Tjernberg will take on a new role as a Senior Advisor to MSAB and keep contributing with his extensive knowledge and experience.

About Edastra
Edastra is focusing on investing in entrepreneurs who solve great challenges in modern times. Digitalization and sustainability are essential elements in our analysis since they count as the most important trends in present time. These trends offer profitable opportunities by creating shareholder value as well as generating societal benefits, our profound conviction is that these objectives can go hand-in-hand.

About Cervantes
Cervantes Capital is an investment firm with a strong belief in being an active and committed owner. The main focus is long-term investments in listed equities in small- and midcap Swedish companies.

About Grenspecialisten
AB Grenspecialisten is an investment firm owned by Martin Gren, co-founder of Axis Communications. Grenspecialisten invests long-term in growing small cap companies, primarily within IT and Life Science.

This Information was submitted for publication on April 29 2021 kl. 12.40 CEST.

For more information please contact:
Daniel Hilmgård, CFO MSAB, daniel.hilmgard@msab.com , +46 70 996 8333

About MSAB
MSAB is a world leader in forensic technology for extracting and analyzing data in seized mobile devices. The company develops high-quality and easy-to-use software for law enforcement organizations, such as police, military, and customs. The products, which have become a de facto standard for securing evidence in criminal investigations, can be supplemented with reporting tools and a large range of training with certifications within a holistic method for forensic science. The company serves customers in more than 100 countries worldwide, through its own sales offices and through distributors. MSAB is listed on Nasdaq Stockholm under the ticker name: MSAB B. www.msab.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin

Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

HiddenA line styled icon from Orion Icon Library.Eye